We are currently experiencing technical issues due to the Microsoft outage. This will affect delivery of multi-factor authentication emails, invoice emails and service emails. We apologise for the disruption.

Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

Home CompaniesTherapeuticsMD Inc

TherapeuticsMD Inc

Healthcare Drug Manufacturers - Specialty & Generic
PortfolioPortfolio WatchlistWatchlist
Company price
1.8326 USD -0.02 ( 0.94%)
Last update at 2026-11-12T14:42:00Z
VOLUME
429
Market Cap
25.37M

Momentum Score

…

TherapeuticsMD, Inc. operates as a pharmaceutical royalty company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY, BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brand names. The company sells its prescription pharmaceutical products and prenatal vitamin products through wholesale distributors and retail pharmacy distributors. TherapeuticsMD, Inc. was founded in 2008 and is headquartered in Boca Raton, Florida.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
1.83
Low
1.83
High
52 Week Price Range
1.84
Low
4.50
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

TherapeuticsMD is a U.S. specialty pharmaceutical company focused on developing and commercializing prescription therapies for women's health, particularly menopause and contraceptive care. Long-term growth may be supported by an aging female population, greater clinical attention to menopause symptoms, and potential expansion of product uptake and geographic reach. The company could appeal to investors seeking niche exposure to prescription women's-health products with an established commercial presence.

Investors should monitor revenue concentration on a small product portfolio, commercialization and reimbursement challenges, competition from generics and larger pharmaceutical companies, and ongoing financing and execution risk that could affect operations.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
1.85
Dividend Yield
-
Revenue TTM
1.30M
Revenue Per Share
0.12
Gross Profit TTM
68.11M
Debt / Equity
0.27
ROE
-23.90%
Net Debt
3.68M
ROCE
-23.38%
Diluted EPS TTM
-0.57

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Income before tax -7.74M 1.07M -172.41M -183.52M -176.14M
Net income -10.28M 112.00M -205.60M -212.70M -196.03M
Selling general administrative 18.96M 57.90M 92.60M 76.95M 58.81M
Selling and marketing expenses - - 108.19M 117.05M 114.23M
Gross profit 0.38M 68.57M 68.11M 48.90M 43.31M
Reconciled depreciation 0.59M 1.19M 4.09M 4.07M 1.39M
Ebit -8.52M 20.14M -139.77M -155.54M -151.21M
Ebitda -7.60M 21.33M -135.41M -150.88M -147.31M
Depreciation and amortization 0.92M 1.19M 4.37M 4.66M 3.89M
Non operating income net other - - 0.27M 0.60M -
Operating income -8.52M 20.14M -139.77M -155.54M -151.21M
Other operating expenses 9.82M 59.30M 226.72M 220.41M 200.85M
Interest expense - 12.27M 32.92M 28.58M 17.38M
Tax provision - 0.29M 0.55M 0.00M 0.00M
Interest income - - - - 0.00M
Net interest income - -38.52M -32.92M -28.58M -17.38M
Income tax expense -0.04M -91.86M 33.19M 29.18M 19.88M
Total revenue 1.30M 69.96M 86.95M 64.87M 49.65M
Total operating expenses 8.90M 57.90M 207.88M 204.44M 194.52M
Cost of revenue 0.92M 1.40M 18.84M 15.97M 6.33M
Total other income expense net 0.78M -19.06M -32.65M -27.98M -24.94M
Net income from continuing ops 42.30M 1.07M -172.41M -183.52M -176.14M
Net income applicable to common shares - - -172.41M -183.52M -176.14M
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 43.31M 90.46M 169.47M 181.61M 265.99M
Intangible assets 6.10M 6.94M 40.32M 41.44M 44.48M
Other current assets 2.04M 2.53M 10.55M 7.54M 11.33M
Total liab 14.02M 55.31M 263.09M 305.61M 256.78M
Total stockholder equity 29.29M 35.14M -93.62M -124.00M 9.20M
Other current liab 5.35M 43.29M 4.72M 38.17M 33.82M
Common stock 0.01M 0.01M 0.43M 0.30M 0.27M
Capital stock - 0.01M 0.43M 0.30M 0.27M
Retained earnings -949.64M -939.36M -1051.36M -878.95M -695.42M
Other liab - - 0.00M - -
Other assets 0.00M - 0.00M 46.02M 0.47M
Cash 4.33M 38.07M 65.12M 80.49M 160.83M
Total current liabilities 6.85M 46.84M 252.89M 59.24M 53.00M
Current deferred revenue - - 39.59M -2.25M -1.50M
Net debt 3.68M -29.31M 131.21M 165.89M 42.95M
Short term debt 1.47M 1.39M 188.27M 2.25M 1.50M
Short long term debt - - 188.27M - -
Short long term debt total 8.01M 8.76M 196.33M 246.37M 203.78M
Other stockholder equity 978.92M 974.50M 957.31M 754.64M 704.35M
Property plant equipment - - 0.01M 1.94M 12.62M
Total current assets 9.46M 55.35M 119.47M 128.40M 208.42M
Net tangible assets - - -0.13M -124.00M -35.28M
Net receivables 3.09M - 36.18M 32.38M 24.40M
Long term debt - - - 237.70M 194.63M
Inventory - - 7.62M 7.99M 11.86M
Accounts payable 0.03M 2.16M 20.32M 21.07M 19.18M
Accumulated other comprehensive income 0.00M - - - -0.97M
Common stock total equity - - 0.43M 0.30M 0.27M
Retained earnings total equity - - -1051.36M -878.95M -
Non currrent assets other 2.39M 20.51M 0.25M 0.25M 0.47M
Non current assets total 33.85M 35.11M 50.00M 53.21M 57.57M
Capital lease obligations - 8.76M 8.06M 10.93M 10.65M
Long term debt total - - - 237.70M 194.63M
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Investments 223.76M 223.48M -2.22M -1.60M -23.91M
Change to liabilities - - -0.75M 4.79M -3.56M
Total cashflows from investing activities - - -2.22M -1.60M -23.91M
Net borrowings - - -50.00M 48.75M 118.34M
Total cash from financing activities 3.15M -235.21M 129.55M 80.72M 188.83M
Change to operating activities - - 5.27M 6.33M 11.79M
Net income -7.70M 1.07M -172.41M -183.52M -176.14M
Change in cash -44.99M -15.80M -15.36M -80.34M -0.78M
Begin period cash flow 49.32M 65.12M 80.49M 160.83M 161.61M
End period cash flow 4.33M 49.32M 65.12M 80.49M 160.83M
Total cash from operating activities -48.14M -4.08M -142.69M -159.47M -165.70M
Issuance of capital stock 22.85M 24.15M 184.12M 31.70M 77.03M
Depreciation 0.92M 1.19M 4.09M 4.07M 1.39M
Other cashflows from investing activities - - -2.19M -1.39M -0.02M
Change to inventory - 0.59M -0.71M -3.34M -8.59M
Change to account receivables - 4.28M -4.33M -8.20M -13.64M
Sale purchase of stock - -38.66M 184.44M 31.97M 77.14M
Other cashflows from financing activities 3.15M -15.77M -4.56M 97.77M 193.46M
Change to netincome - - 20.46M 19.50M 22.20M
Capital expenditures 0.00M 0.35M 2.22M 1.60M 23.89M
Change receivables - - -4.33M -8.20M -
Cash flows other operating - - 4.21M 8.00M -
Cash and cash equivalents changes - - -15.36M -80.34M -
Change in working capital -17.45M -4.09M -0.52M -3.32M -14.00M
Stock based compensation 1.27M 11.57M 18.12M 10.68M 10.68M
Other non cash items -19.94M -13.83M 7.49M 10.87M 1.92M
Free cash flow -48.14M -4.43M -144.92M -161.07M -189.59M

Peer Comparison*

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
TXMD
TherapeuticsMD Inc		 -0.02
0.94%		 1.83 - 2.29 17.63 0.78 20.45 -3.50
MKKGY
Merck KGaA ADR		 -0.74
2.19%		 33.06 21.25 14.93 3.10 2.14 3.60 12.98
MKGAF
MERCK Kommanditgesellschaft auf Aktien		 -
-%		 170.05 24.86 15.11 3.13 1.98 3.08 18.89
TAK
Takeda Pharmaceutical Co Ltd ADR		 0.34
1.66%		 21.18 - 10.96 0.01 1.20 2.94 23.11
TKPHF
Takeda Pharmaceutical Co. Ltd.		 -
-%		 41.72 - 10.66 0.01 1.16 2.94 23.11

Profile*

TherapeuticsMD Inc

TherapeuticsMD, Inc. operates as a pharmaceutical royalty company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY, BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brand names. The company sells its prescription pharmaceutical products and prenatal vitamin products through wholesale distributors and retail pharmacy distributors. TherapeuticsMD, Inc. was founded in 2008 and is headquartered in Boca Raton, Florida.

951 Yamato Road, Boca Raton, FL, United States, 33431

561 961 1900

https://www.therapeuticsmd.com

1

Name Title Year Born
Governor Thomas G. Thompson Exec. Chairman 1942
Mr. Hugh O'Dowd M.B.A. Pres & Director 1965
Mr. Robert G. Finizio Co-Founder 1971
Mr. Marlan D. Walker J.D. Gen. Counsel & Secretay 1975
Dr. Brian A. Bernick F.A.C.O.G., M.D. Co-Founder,Co-CEO & Chief Medical Officer 1968
Mr. Mark A. Glickman Co-CEO & Chief Bus. Officer 1966
Mr. Michael C. Donegan Interim CFO, Chief Accounting Officer and Principal Financial & Accounting Officer 1968
Ms. Daniella Silva Chief Compliance Officer 1986
Mr. Benjamin Foulk VP of HR 1970
Mr. Mitchell L. Krassan Exec. VP and Chief Strategy & Performance Officer 1966

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

DAR
GBX 8.30
+23.42%
VTY
GBX 276.20
+8.23%
GTCO
GBX 0.09
+6.98%
GLV
GBX 2.34
+6.36%
BUR
GBX 249.20
+5.95%
TMI
GBX 0.72
-6.49%
HSBA
GBX 1291.40
-5.42%
RKT
GBX 5218.00
-4.85%
TGA
GBX 643.00
-4.03%
RKH
GBX 61.70
-3.89%

Equity Sectors*

  • Basic Materials

    -1.70%

  • Communication Services

    +0.33%

  • Consumer Cyclical

    +0.45%

  • Consumer Defensive

    -0.56%

  • Energy

    -0.25%

  • Financial Services

    +0.49%

  • Healthcare

    +0.20%

  • Industrials

    +0.74%

  • Real Estate

    +1.71%

  • Technology

    -2.81%

  • Utilities

    +0.28%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Cookies on this website

We use some essential cookies to make this site work. We also set analytics and marketing cookies, described below, to understand how you use the site and to measure our advertising. For more detailed information, see our Cookie Policy, Privacy Policy and Terms and Conditions.

Essential cookies

These cookies are necessary for core functionality, such as security, your shopping cart, remembering your cookie choice, and your progress through a report or free-trial request you started. They always need to be on.

Analytics cookies

We use analytics cookies to understand how visitors use the site — the pages visited, time spent, and where visitors came from.

Marketing cookies

These help us measure how effective our advertising is, such as recording actions you take after clicking one of our ads. If you don't enable this, you may still see our ads, but they won't be measured this way.

Support

Hi! How can we help you today?

Loading…